Understand the source comparison
Comparison Table: Best Peptides for Diabetic Neuropathy Research
BPC-157 VEGF upregulation, angiogenesis, FAK-paxillin pathway activation Case reports and observational data only. No RCTs in diabetic neuropathy Subcutaneous or intramuscular injection 250–500 mcg daily in research models Strongest preclinical evidence for ne
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis, FAK-paxillin pathway activation
- Case reports and observational data only. No RCTs in diabetic neuropathy
- Subcutaneous or intramuscular injection
- 250–500 mcg daily in research models
- Strongest preclinical evidence for nerve regeneration but lacks human validation in diabetic neuropathy specifically
- Cerebrolysin
- BDNF, NGF, CNTF delivery; Trk receptor activation
- Multiple RCTs in diabetic polyneuropathy with positive nerve conduction outcomes
- Intramuscular injection
- 30 mL (3 ampules) 3× weekly for 10 weeks in clinical trials
- Only peptide with published RCT data in diabetic neuropathy. Demonstrated measurable NCV improvements
- P21
- CREB pathway activation, synaptic plasticity enhancement
- No diabetic neuropathy trials. CNTF parent compound tested in neurodegenerative diseases
- Subcutaneous injection
- 1–5 mg daily in cognitive research models
- Promising neuroplasticity mechanism but insufficient neuropathy-specific data
- Dihexa
- HGF mimetic, Met receptor agonist, axonal sprouting
- Phase 2 cognitive trial completed. No peripheral neuropathy studies
- Oral or subcutaneous
- 5–10 mg daily in cognitive enhancement research
- Unique oral bioavailability but diabetic neuropathy application remains theoretical